Invitamos a leer el artículo: “5-Hydroxytryptamine receptors in GtoPdb v.2023.1”, en la que colaboró el Doctor Carlos M. Villalon, Investigador de Cinvestav Sede Sur
Autores: Rodrigo Andrade, Nicholas M. Barnes, Gordon Baxter, Joel Bockaert, Theresa Branchek, Amy Butler,Marlene L. Cohen, Aline Dumuis, Richard M. Eglen, Manfred Göthert, Mark Hamblin, Michel Hamon,Paul R. Hartig, René Hen, Julie Hensler, Katharine Herrick-Davis, Rebecca Hills, Daniel Hoyer,Patrick P. A. Humphrey, Klaus Peter Latté, Luc Maroteaux, Graeme R. Martin, Derek N. Middlemiss,Ewan Mylecharane, John Neumaier, Stephen J. Peroutka, John A. Peters, Bryan Roth, Pramod R.Saxena, Trevor Sharp, Andrew Sleight, Carlos M. Villalon y Frank Yocca
Abstract: 5-HT receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on 5-HT receptors [198] and subsequently revised [180]) are, with the exception of the ionotropic 5-HT3 class, GPCRs where the endogenous agonist is 5-hydroxytryptamine. The diversity of metabotropic 5-HT receptors is increased by alternative splicing that produces isoforms of the 5-HT2A (non-functional), 5-HT2C (non-functional), 5-HT4, 5-HT6 (non-functional) and 5-HT7 receptors. Unique amongst the GPCRs, RNA editing produces 5-HT2C receptor isoforms that differ in function, such as efficiency and specificity of coupling to Gq/11 and also pharmacology [40, 491]. Most 5-HT receptors (except 5-ht1e and 5-ht5b) play specific roles mediating functional responses in different tissues (reviewed by [471, 387]).